Triple-negative breast cancer (TNBC), which comprises 15–20% of all breast cancer, is considered the most aggressive type of breast cancer due to the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expressions for treatments [5,6,7]. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.